User profiles for C. Mueller-Tidow
Carsten Müller-TidowVerified email at cmt3.de Cited by 29009 |
Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients
…, P Dreger, C Mueller-Tidow… - Blood, The Journal …, 2022 - ashpublications.org
Three reports address the protection of the vulnerable population of patients with hematologic
malignancies in the face of the ongoing COVID pandemic. The reports suggest that some …
malignancies in the face of the ongoing COVID pandemic. The reports suggest that some …
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
…, L Bullinger, G Hess, C Mueller-Tidow… - Blood …, 2021 - ashpublications.org
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in
combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (…
combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (…
Cryopreservation does not alter main characteristics of good manufacturing process–grade human multipotent mesenchymal stromal cells including …
…, A Moegel, K Hoffmann, C Hoefers, C Mueller-Tidow… - Cytotherapy, 2015 - Elsevier
… C. Mueller-Tidow: data analysis and manuscript writing. LP Mueller: conception and
design, provision of study material, data collection and analysis, manuscript writing and final …
design, provision of study material, data collection and analysis, manuscript writing and final …
[HTML][HTML] Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia
…, C Akiba, R Paquette, W Chien, C Mueller-Tidow… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Survival of cancer cells relies on the unfolded protein response (UPR) to resist stress triggered
by the accumulation of misfolded proteins within the endoplasmic reticulum (ER). The …
by the accumulation of misfolded proteins within the endoplasmic reticulum (ER). The …
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)
…, A Gratwohl, CR Choudhary, C Mueller-Tidow… - Blood, 2005 - ashpublications.org
Fms-like tyrosine kinase 3 (FLT3) receptor mutations as internal tandem duplication (ITD) or
within the kinase domain are detected in up to 35% of patients with acute myeloid leukemia (…
within the kinase domain are detected in up to 35% of patients with acute myeloid leukemia (…
[HTML][HTML] Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non–small-cell lung cancer
…, R Voss, A Marra, A Faldum, C Mueller-Tidow… - Journal of Thoracic …, 2014 - Elsevier
Introduction Apoptosis is a crucial pathway in tumor growth and metastatic development.
Apoptotic proteins regulate the underlying molecular cascades and are thought to modulate the …
Apoptotic proteins regulate the underlying molecular cascades and are thought to modulate the …
[HTML][HTML] Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL
Background: T lymphocyte collection through leukapheresis is an essential step for chimeric
antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily …
antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily …
[HTML][HTML] NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration
…, S Goellner, F Zhou, B Edemir, C Mueller-Tidow - Oncogene, 2021 - nature.com
… c and d Representative microscopy images of colony formation assays using A549 scr control
and NOP10 KD cells (c, left) and Pc-9 scr control and NOP10 KO cells (d, left). Number of …
and NOP10 KD cells (c, left) and Pc-9 scr control and NOP10 KO cells (d, left). Number of …
End‐stage renal disease, dialysis, kidney transplantation and their impact on CD4+ T‐cell differentiation
…, C Morath, V Eckstein, A Ho, C Mueller‐Tidow… - …, 2018 - Wiley Online Library
Premature aging of both CD 4 + regulatory T (Treg) and CD 4 + responder‐T (Tresp) cells in
patients with end‐stage renal disease ( ESRD ) is expected to affect the success of later …
patients with end‐stage renal disease ( ESRD ) is expected to affect the success of later …
Trabectedin: Supportive care strategies and safety profile
…, F Jahn, B Jordan, T Kegel, C Mueller-Tidow… - Critical reviews in …, 2015 - Elsevier
Trabectedin is an approved antineoplastic agent for the treatment of adult patients with
advanced soft tissue sarcomas or in combination with pegylated liposomal doxorubicin (PLD) in …
advanced soft tissue sarcomas or in combination with pegylated liposomal doxorubicin (PLD) in …